Clinical Management of Respiratory Adverse Events Associated With Amikacin Liposome Inhalation Suspension: Results From a Patient Survey
Sign Up to like & getrecommendations! Published in 2020 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofaa079
Abstract: Abstract Patients with Mycobacterium avium complex lung disease treated with amikacin liposome inhalation suspension (ALIS) at 2 clinics in the United States were surveyed to assess the frequency and management of ALIS-associated respiratory adverse events.… read more here.
Keywords: amikacin liposome; management; respiratory adverse; adverse events ... See more keywords